TransHeps AG

Safer drugs for patients via DILI causality assessments.

We address drug-induced liver injury (DILI) to provide critical support in clinical trials before drug approval. DILI is an acute form of liver injury caused by drug intake. It cannot be confirmed by standard liver tests.
We provide DILI causality assessments to show the real cause for a DILI. The client can use this information to determine the right patients to safely use the prospective drug. For pharma companies, a DILI often means that their drug approval will fail and they lose their investments of over CHF 1-3 billion, so our test is extremely valuable for them.
Our founders are professors in the field of toxicology, clinical pharmacology and renowned DILI experts, as well as a seasoned startup CFO. We estimate the total market size for our products to be CHF 28.5 billion.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

25.02.2024

Successful FDA hearing

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (10'000) 2024

Website